`Share of Unit Sales
`
`EXHIBIT 2048
`
`PYRE
`a
`(°)
`
`PAB
`
`17.0%
`
`crea
`
`Bc
`
`Trey
`°
`
`12.6%
`
`11.6%
`
`Ura
`
`eet
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`5.1%
`
`2006
`
`2007
`
`100%
`
`90%
`
`80%
`
`70%
`
`60%
`
`50%
`
`40%
`
`30%
`
`20%
`
`10%
`
`0%
`
`BTRAVATAN Z® mB TRAVATAN® gLUMIGAN® §ZIOPTAN™ @XALATAN® S RESCULA® mLatanoprost mTravoprost mBimatoprost
`Source:
`/QVIA
`Note: Units are measured in eaches. TRAVATAN Z® waslaunched in October 2006. Data for 2017 are available through October. The values for November
`and December 2017 are projected on the basis of the average yearly proportion of the unit sales in November and December for the previous three years. For
`bimatoprost, the values for November and December 2017 are projected on the basis of the proportion of the unit sales in November and December for the
`previous year.
`
`CONFIDENTIAL-PROTECTIVE ORDER MATERIAL
`
`ALCON2048
`Argentum Pharm. LLC v. Alcon Research, Ltd.
`Case IPR2017-01053
`
`